| Pharmaceutical Information |
| Drug Name |
Saxagliptin hydrochloride |
| Drug ID |
BADD_D01993 |
| Description |
Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. |
| Indications and Usage |
Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy. |
| Marketing Status |
approved |
| ATC Code |
A10BH03 |
| DrugBank ID |
DB06335
|
| KEGG ID |
D10262
|
| MeSH ID |
C502994
|
| PubChem ID |
49800073
|
| TTD Drug ID |
D0Y6QC
|
| NDC Product Code |
55111-960; 50370-0039 |
| UNII |
Z8J84YIX6L
|
| Synonyms |
saxagliptin | 3-hydroxyadamantylglycine-4,5-methanoprolinenitrile hydrate | Onglyza | BMS 477118 | BMS477118 | BMS-477118 |
|
| Chemical Information |
| Molecular Formula |
C18H26ClN3O2 |
| CAS Registry Number |
709031-78-7 |
| SMILES |
C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N.Cl |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
